Plenvu

Last updated on RxList: 6/14/2021
Drug Description

What is Plenvu and how is it used?

Plenvu is a prescription medicine used as Colonoscopy Bowel Preparation. Plenvu may be used alone or with other medications.

Plenvu belongs to a class of drugs called Bowel Preps.

It is not known if Plenvu is safe and effective in children.

What are the possible side effects of Plenvu?

Plenvu may cause serious side effects including:

  • hives,
  • difficulty breathing,
  • swelling of your face, lips, tongue, or throat,
  • vomit that is bloody or looks like coffee grounds,
  • chest pain,
  • fast, slow, or irregular heartbeat,
  • dizziness,
  • fainting seizures,
  • shortness of breath,
  • changes in the amount of urine,
  • severe stomach pain,
  • bloody stools,
  • rectal bleeding, and
  • severe dizziness

Get medical help right away, if you have any of the symptoms listed above.

The most common side effects of Plenvu include:

  • nausea,
  • bloating, and
  • feeling of fullness in the stomach

Tell the doctor if you have any side effect that bothers you or that does not go away.

These are not all the possible side effects of Plenvu. For more information, ask your doctor or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

DESCRIPTION

The active ingredients contained in PLENVU are provided in Table 3.

Table 3: Details of Active Ingredients contained in PLENVU

Chemical Name Chemical Formula Average Molecular Weight (g/mol) Chemical Structure
Polyethylene Glycol (PEG) 3350 H-(OCH2-CH2)n-OH 3350
Ppolyethylene glycol 3350 - Structural Formula Illustration
Sodium Ascorbate C6H7NaO6 198.1
Sodium ascorbate - Structural Formula Illustration
Sodium Sulfate Na2SO4 142.0
Sodium sulfate - Structural Formula Illustration
Ascorbic Acid C6H8O6 176.1
Ascorbic acid - Structural Formula Illustration
Sodium Chloride NaCl 58.4 Na+ Cl-
Potassium Chloride KCl 74.6 K+ Cl+

PLENVU (polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride for oral solution) is an osmotic laxative consisting of three pouches (one for Dose 1, one for Dose 2 Pouch A and one for Dose 2 Pouch B) containing white to yellow powder for reconstitution.

Dose 1 contains 100 grams of PEG 3350, NF; 9 grams of sodium sulfate, NF; 2 grams of sodium chloride, USP/NF; and 1 gram of potassium chloride, USP/NF; and the following excipients: sucralose, NF; encapsulated citric acid; and mango flavoring. When Dose 1 is dissolved in water to a volume of 16 fluid ounces, PLENVU Dose 1 (PEG 3350, sodium sulfate, sodium chloride and potassium chloride) is an oral solution having a mango flavor.

Each Dose 2 Pouch A contains 40 grams of PEG 3350, NF; 3.2 grams of sodium chloride, USP/NF; and 1.2 grams of potassium chloride, USP/NF and the following excipients: aspartame, NF and fruit punch flavoring.

Each Dose 2 Pouch B contains 48.11 grams of sodium ascorbate, USP/NF; and 7.54 grams of ascorbic acid, USP/NF.

When Dose 2 Pouch A and Dose 2 Pouch B are dissolved together in water to a volume of 16 fluid ounces, PLENVU Dose 2 (sodium ascorbate, PEG 3350, ascorbic acid, sodium chloride and potassium chloride) is an oral solution having a fruit punch flavor.

The entire, reconstituted, 32 fluid ounces of PLENVU bowel preparation contains 140 grams of PEG 3350, 48.11 grams of sodium ascorbate, 9 grams of sodium sulfate, 7.54 grams of ascorbic acid, 5.2 grams of sodium chloride and 2.2 grams of potassium chloride and the following excipients: aspartame, sucralose, encapsulated citric acid, mango and fruit punch flavorings.

A mixing container for reconstitution is enclosed.

Phenylketonurics

Contains Phenylalanine 491 mg per treatment.

Contains no ingredient made from a gluten-containing grain (wheat, barley, or rye).

Indications & Dosage

2 pharmacies near 94043 have coupons for Colyte with Flavor Packs (Brand Names:Plenvu for 4000ML of 240GM)

Walgreens
Walgreens
$85.69

Est. Regular Price

$63.18

with free coupon

View Coupon
Safeway Pharmacy
Safeway Pharmacy
$85.69

Est. Regular Price

$64.5

with free coupon

View Coupon

INDICATIONS

PLENVU® is indicated for cleansing of the colon in preparation for colonoscopy in adults.

DOSAGE AND ADMINISTRATION

Important Preparation And Administration Instructions

  • Correct fluid and electrolyte abnormalities before treatment with PLENVU [see WARNINGS AND PRECAUTIONS].

Two doses of PLENVU are required for a complete preparation for colonoscopy. The time interval between the two doses depends on the regimen prescribed and the planned timing of the colonoscopy procedure [see Two-Day Split-Dosing Regimen, One-Day Morning Dosing Regimen].

  • The “Two-Day Split-Dosing” method consists of two separate doses: the first dose is taken the evening before the colonoscopy and the second dose is taken the next day, the morning of the day of the colonoscopy [see Two-Day Split-Dosing Regimen].
  • The “One-Day Morning Dosing” method consists of two separate doses: both doses are taken in the morning of the day of the colonoscopy, with a minimum of 2 hours between the start of the first dose and the start of the second dose [see One-Day Morning Dosing Regimen].
  • PLENVU must be reconstituted in the mixing container with water prior to ingestion. It may take 2 to 3 minutes for complete dissolution. Do not reconstitute with other liquids and/or add starch-based thickeners to the mixing container [see WARNINGS AND PRECAUTIONS].
  • Additional clear liquids (including water) must be consumed in both dosing regimens [see Two-Day Split-Dosing Regimen, One-Day Morning Dosing Regimen, WARNINGS AND PRECAUTIONS].
  • Consume only clear liquids (no solid food) from the start of PLENVU treatment until after the colonoscopy.
  • Do not eat or drink alcohol, milk, anything colored red or purple or any other foods containing pulp material.
  • Do not take other laxatives while taking PLENVU.
  • Do not take oral medications within 1 hour before or after starting each dose of PLENVU [see DRUG INTERACTIONS].
  • Ensure completion of Dose 2, including all additional liquids, at least 2 hours before the colonoscopy.

Two-Day Split-Dosing Regimen

The Two-Day Split-Dosing Regimen commences in the evening of the day before the colonoscopy.

Instruct adult patients that on the day before the clinical procedure, they can consume a light breakfast followed by a light lunch, which must be completed at least 3 hours prior to the start of the first PLENVU dose.

Instruct patients to take two separate doses in conjunction with clear liquids as follows:

Dose 1 – In The Evening Before The Colonoscopy, Between Approximately 4 pm And 8 pm
  1. Empty the contents of Dose 1 into the mixing container that comes with PLENVU.
  2. Add water to the fill line on the mixing container (at least 16 fluid ounces). Do not add other ingredients to the PLENVU solution.
  3. Thoroughly mix with a spoon or shake with lid on securely until completely dissolved (which may take 2 to 3 minutes).
  4. Drink over the next 30 minutes. Be sure to drink all of the solution.
  5. Refill the mixing container to the fill line (at least 16 fluid ounces) with clear liquids and drink over the next 30 minutes.
  6. Consume additional clear liquids during the evening.
  7. If severe bloating, abdominal distention, or abdominal pain occurs following the first dose, delay the second dose until the symptoms resolve.
Dose 2 – The Next Morning, On The Day Of The Colonoscopy, Approximately 12 Hours After The Start Of Dose 1 (Between Approximately 4 am And 8 am)
  1. Empty the contents of Dose 2 Pouch A and Dose 2 Pouch B into the mixing container that comes with PLENVU.
  2. Add water to the fill line on the mixing container (at least 16 fluid ounces). Do not add other ingredients to the PLENVU solution.
  3. Thoroughly mix with a spoon or shake with lid on securely until completely dissolved (which may take 2 to 3 minutes). Drink over the next 30 minutes. Be sure to drink all of the solution.
  4. Refill the mixing container to the fill line (at least 16 fluid ounces) with clear liquids and drink over the next 30 minutes.
  5. Consume additional water or clear liquids up to 2 hours before the colonoscopy or as prescribed by your doctor.
    Then stop drinking liquids until after the colonoscopy.

Stop drinking PLENVU temporarily or drink each portion at longer intervals if severe bloating, abdominal discomfort or distention occurs, until these symptoms resolve.

One-Day Morning Dosing Regimen

The One-Day Morning Dosing Regimen commences in the morning of the day of the colonoscopy.

Instruct adult patients that on the day before the clinical procedure, they can consume a light breakfast followed by a light lunch, and clear broth soup and/or plain yogurt for dinner, which should be completed by approximately 8 pm.

Instruct patients to take two separate doses in conjunction with clear liquids as follows:

Dose 1 – On The Day Of The Colonoscopy, Between Approximately 3 am And 7 am
  1. Empty the contents of Dose 1 into the mixing container that comes with PLENVU.
  2. Add water to the fill line on the mixing container (at least 16 fluid ounces). Do not add other ingredients to the PLENVU solution.
  3. Thoroughly mix with a spoon or shake with lid on securely until completely dissolved (which may take 2 to 3 minutes).
  4. Drink over the next 30 minutes. Be sure to drink all of the solution.
  5. Refill the mixing container to the fill line (at least 16 fluid ounces) with clear liquids and drink over the next 30 minutes.
  6. If severe bloating, abdominal distention, or abdominal pain occurs following the first dose, delay the second dose until the symptoms resolve.
Dose 2 – On The Day Of The Colonoscopy, A Minimum Of 2 Hours After The Start Of Dose 1
  1. Empty the contents of Dose 2 Pouch A and Dose 2 Pouch B into the mixing container that comes with PLENVU.
  2. Add water to the fill line on the mixing container (at least 16 fluid ounces). Do not add other ingredients to the PLENVU solution.
  3. Thoroughly mix with a spoon or shake with lid on securely until completely dissolved (which may take 2 to 3 minutes). Drink over the next 30 minutes. Be sure to drink all of the solution.
  4. Refill the mixing container to the fill line (at least 16 fluid ounces) with clear liquids and drink over the next 30 minutes.
  5. Consume additional water or clear liquids up to 2 hours before the colonoscopy or as prescribed by your doctor.
    Then stop drinking liquids until after the colonoscopy.

Stop drinking PLENVU temporarily or drink each portion at longer intervals if severe bloating, abdominal discomfort or distention occurs, until these symptoms resolve.

Storage

After reconstitution, keep PLENVU solution at room temperature, between 68°F to 77°F (20°C to 25°C) [see USP Controlled Room Temperature]. The solution may also be stored in a refrigerator. Use within 24 hours after it is mixed in water.

HOW SUPPLIED

Dosage Forms And Strengths

PLENVU (polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride for oral solution) is supplied as a white to yellow powder for reconstitution.

First dose: one pouch labeled Dose 1; Second dose: two pouches labeled Dose 2 Pouch A and Dose 2 Pouch B.

  • Dose 1 contains 100 grams of polyethylene glycol (PEG) 3350, NF; 9 grams of sodium sulfate, USP; 2 grams of sodium chloride, USP/NF; and 1 gram of potassium chloride, USP/NF.
  • Dose 2 Pouch A contains 40 grams of PEG 3350, NF; 3.2 grams of sodium chloride, USP/NF; and 1.2 grams of potassium chloride, USP/NF.
  • Dose 2 Pouch B contains 48.11 grams of sodium ascorbate, USP/NF; and 7.54 grams of ascorbic acid, USP/NF.

Storage And Handling

PLENVU (polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride for oral solution) is supplied as a white to yellow powder for reconstitution.

Dose 1 contains 100 grams of PEG 3350, NF; 9 grams of sodium sulfate, USP; 2 grams of sodium chloride, USP/NF; and 1 gram of potassium chloride, USP/NF: NDC 65649-400-01.

Dose 2 Pouch A contains 40 grams of PEG 3350, NF; 3.2 grams of sodium chloride, USP/NF; and 1.2 grams of potassium chloride, USP/NF: NDC 65649-400-01.

Dose 2 Pouch B contains 48.11 grams of sodium ascorbate, USP/NF; and 7.54 grams of ascorbic acid, USP/NF: NDC 65649-400-01.

PLENVU, single-use inner carton: The inner carton contains three pouches labeled Dose 1, Dose 2 Pouch A and Dose 2 Pouch B: NDC 65649-400-01.

PLENVU, single-use outer carton: Each outer carton contains the inner carton, prescribing information and patient information and a disposable mixing container with lid for reconstitution of PLENVU: NDC 65649-400-01.

Storage

Store pack at room temperature, between 68°F to 77°F (20°C to 25°C) with excursions permitted to 59°F to 86°F (15°C to 30°C) [see USP Controlled Room Temperature]. The pack may be stored in a refrigerator.

Manufactured by: Norgine Limited, 7 Tir-y-berth Industrial Estate, New Road, Tir-y-berth, Hengoed, CF82 8SJ, United Kingdom (GBR). Revised: May 2021

SLIDESHOW

Digestive Disorders: Common Misconceptions See Slideshow
Side Effects

SIDE EFFECTS

The following serious or otherwise important adverse reactions for bowel preparations are described elsewhere in the labeling:

  • Serious Fluid and Electrolyte Abnormalities [see WARNINGS AND PRECAUTIONS]
  • Cardiac Arrhythmias [see WARNINGS AND PRECAUTIONS]
  • Seizures [see WARNINGS AND PRECAUTIONS]
  • Patients with Renal Impairment [see WARNINGS AND PRECAUTIONS]
  • Colonic Mucosal Ulceration, Ischemic Colitis and Ulcerative Colitis [see WARNINGS AND PRECAUTIONS]
  • Patients with Significant Gastrointestinal Disease [see WARNINGS AND PRECAUTIONS]
  • Aspiration [see WARNINGS AND PRECAUTIONS]
  • Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency [see WARNINGS AND PRECAUTIONS]
  • Risks in Patients with Phenylketonuria [see WARNINGS AND PRECAUTIONS]
  • Hypersensitivity Reactions [see WARNINGS AND PRECAUTIONS]

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of PLENVU as a Two-Day Split-Dosing and One-Day Morning Dosing Regimen was evaluated in two randomized, parallel group, multicenter, investigator-blinded clinical trials (Two-Day Split-Dosing in the NOCT and MORA trials and One-Day Morning Dosing in the MORA trial) in 1351 adult patients undergoing colonoscopy. The mean age of the study population was 56 years (range 18 to 86 years), 92% of patients were Caucasian and 51% were female. In the NOCT trial, 61% of patients had mild renal impairment. In the MORA trial, 67% had mild renal impairment and 5% had moderate renal impairment. Patients with severe renal impairment were not enrolled in the clinical trials of PLENVU [see Clinical Studies].

The most common adverse reactions (>2%) in the PLENVU treatment groups in both trials were: nausea, vomiting, dehydration and abdominal pain/discomfort.

Table 1 and Table 2 display adverse reactions reported in at least 1% of patients in one or more treatment group(s) in the NOCT and MORA trials, respectively. Since diarrhea was considered as a part of the efficacy assessment, it was not defined as an adverse reaction in these trials.

Table 1: Common Adverse Reactions* in Patients Undergoing Colonoscopy in the NOCT Trial by Treatment Group

Preferred Term PLENVU
Two-Day Split Dosing Regimen
(N = 275)
%
Trisulfate1
Two-Day Split Dosing Regimen
(N = 271)
%
Nausea 7 2
Vomiting 6 3
Dehydration2 4 2
Abdominal Pain/Discomfort3 2 2
Decline in Glomerular Filtration Rate (GFR)4 2 2
Electrolyte Abnormalities5 2 1
Fatigue 2 1
Headache 2 1
Abdominal Distension 1 1
Gastritis 1 1
Hiatus Hernia 1 0
Nasopharyngitis 1 1
* Reported in at least 1% of patients in either treatment group
N = Total number of patients in the treatment group
1 Trisulfate: Two 6 ounce bottles of oral solution each containing sodium sulfate 17.5 grams, potassium sulfate 3.13 grams, magnesium sulfate 1.6 grams
2 Includes signs and symptoms of dehydration, including dizziness, dry mouth, orthostatic hypotension, pre-syncope, syncope, and thirst
3 Includes abdominal discomfort, abdominal pain, lower abdominal pain, upper abdominal pain, and abdominal tenderness
4 Decreased or abnormal GFR
5 Includes increased anion gap, decreased blood bicarbonate, hypomagnesemia, hyperosmolarity, hypokalemia, hyperkalemia, hypercalcemia, hypernatremia, hyperosmolar state, hyperuricemia, hypocalcemia, and hypophosphatemia

Table 2: Common Adverse Reactions* in Patients Undergoing Colonoscopy in the MORA Trial by Treatment Group

Preferred Term PLENVU
One-Day Morning Dosing Regimen
(N = 271)
%
PLENVU
Two-Day Split Dosing Regimen
(N = 265)
%
2 Liter PEG + Electrolytes Two-Day Split-Dosing Regimen1
(N = 269)
%
Vomiting 7 4 1
Nausea 6 6 3
Dehydration2 4 3 2
Abdominal Pain/ Discomfort3 3 2 3
Hypertension 2 1 0
Headache 1 2 2
Electrolyte Abnormalities4 1 1 0
* Reported in at least 1% of patients in either treatment group
N = Total number of patients in the treatment group
1 2 Liter PEG Plus Electrolytes: Two doses each containing PEG 3350 100 grams, sodium sulfate 7.5 grams, sodium chloride 2.691 grams, potassium chloride 1.015 grams, sodium ascorbate 5.9 grams, and ascorbic acid 4.7 grams
2 Includes signs and symptoms of dehydration, including dizziness, dry mouth, orthostatic hypotension, pre-syncope, syncope, and thirst
3 Includes abdominal discomfort, abdominal pain, lower abdominal pain, upper abdominal pain, and abdominal tenderness
4 Includes increased anion gap, decreased blood bicarbonate, hypomagnesemia, increased blood osmolarity, hypokalemia, hyperkalemia, hypercalcemia, hypernatremia, hyperosmolar state, hyperuricemia, hypocalcemia, and hypophosphatemia

Electrolyte Changes

Increases in serum sodium, chloride, calcium, magnesium, phosphate, and urate were noted in more patients treated with PLENVU compared with control in one or both trials. The majority of these changes were transient and not clinically significant. Associated decreases in bicarbonate and increases in serum osmolality were also noted.

Renal Function

Decreases in creatinine clearance and increases in blood urea nitrogen (BUN) were also noted in more patients treated with PLENVU compared to control in both trials. Changes of a magnitude indicative of possible acute renal injury, or worsening of baseline chronic renal impairment, were noted infrequently and occurred at a similar incidence in both PLENVU and comparator arms.

Adverse reactions in patients with mild renal impairment were similar to those in patients with normal renal function.

Less Common Adverse Reactions

Less common adverse reactions (less than 1%) in the NOCT and MORA trials include: anorectal discomfort, hypersensitivity reaction (including rash), migraine, somnolence, asthenia, chills, pains, aches, palpitation, sinus tachycardia, hot flush, and transient increase in liver enzymes.

An additional 235 patients were exposed to the One-Day Morning Dosing Regimen of PLENVU in a third clinical trial, utilizing a comparator not approved in the United States. The adverse reaction profile for patients receiving PLENVU in that trial was similar to what is described above.

Postmarketing Experience

The following adverse reactions have been identified during post-approval use of another oral formulation of polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride or other polyethylene glycol (PEG)-based bowel preparations. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Hypersensitivity: urticaria/rash, pruritus, dermatitis, rhinorrhea dyspnea, chest and throat tightness, fever, angioedema, anaphylaxis and anaphylactic shock [see CONTRAINDICATIONS]

Cardiovascular: arrhythmia, atrial fibrillation, peripheral edema, asystole, and acute pulmonary edema after aspiration

Gastrointestinal: upper gastrointestinal bleeding from a Mallory-Weiss tear, esophageal perforation [usually with gastroesophageal reflux disease (GERD)]

Nervous system: tremor, seizure

Drug Interactions

DRUG INTERACTIONS

Drugs That May Increase Risks Due To Fluid And Electrolyte Abnormalities

Use caution when prescribing PLENVU for patients with conditions and/or who are using medications that increase the risk of fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see WARNINGS AND PRECAUTIONS].

Consider additional patient evaluations as appropriate.

Potential For Reduced Drug Absorption

PLENVU can reduce the absorption of other coadministered drugs. Administer oral medications at least 1 hour before the start of administration of each dose of PLENVU [see DOSAGE AND ADMINISTRATION].

Stimulant Laxatives

Concurrent use of stimulant laxatives and PLENVU may increase the risk of mucosal ulceration or ischemic colitis. Avoid use of stimulant laxatives (e.g., bisacodyl, sodium picosulfate) while taking PLENVU [see WARNINGS AND PRECAUTIONS].

Warnings & Precautions

WARNINGS

Included as part of the "PRECAUTIONS" Section

PRECAUTIONS

Serious Fluid And Electrolyte Abnormalities

Advise patients to hydrate adequately before, during, and after the use of PLENVU. If a patient develops significant vomiting or signs of dehydration after taking PLENVU, consider performing post-colonoscopy laboratory tests (electrolytes, creatinine, and BUN).

Bowel Preparations can cause fluid and electrolyte disturbances, which can lead to serious adverse reactions including cardiac arrhythmias, seizures, and renal impairment. Correct fluid and electrolyte abnormalities before treatment with PLENVU. PLENVU should be used with caution in patients using concomitant medications that increase the risk of electrolyte abnormalities [such as diuretics, angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs)] [see DRUG INTERACTIONS]. Consider performing pre-dose and post-colonoscopy laboratory tests (sodium, potassium, calcium, creatinine, and BUN) in patients receiving these concomitant medications.

Cardiac Arrhythmias

There have been rare reports of serious arrhythmias (including atrial fibrillation) associated with the use of ionic osmotic laxative products for bowel preparation. These occur predominantly in patients with underlying cardiac risk factors and electrolyte disturbances. Use caution when prescribing PLENVU for patients at increased risk of arrhythmias (e.g., patients with a history of prolonged QT, uncontrolled arrhythmias, recent myocardial infarction, unstable angina, congestive heart failure, cardiomyopathy or electrolyte imbalance). Consider pre-dose and post-colonoscopy ECGs in patients at increased risk of serious cardiac arrhythmias.

Seizures

There have been rare reports of generalized tonic-clonic seizures and/or loss of consciousness associated with use of bowel preparation products in patients with no prior history of seizures. The seizure cases were associated with electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, and hypomagnesemia) and low serum osmolality. The neurologic abnormalities resolved with correction of fluid and electrolyte abnormalities.

Use caution when prescribing PLENVU for patients with a history of seizures and in patients at increased risk of seizure, such as patients taking medications that lower the seizure threshold (e.g., tricyclic antidepressants), patients withdrawing from alcohol or benzodiazepines, or patients with known or suspected hyponatremia. [see DRUG INTERACTIONS].

Use In Patients With Renal Impairment

Use PLENVU with caution in patients with renal impairment or patients taking concomitant medications that affect renal function (such as diuretics, ACE inhibitors, angiotensin receptor blockers, or nonsteroidal anti-inflammatory drugs) [see DRUG INTERACTIONS]. These patients may be at risk for renal injury. Advise these patients of the importance of adequate hydration before, during and after the use of PLENVU, and consider performing pre-dose and post-colonoscopy laboratory tests (electrolytes, creatinine, and BUN) in these patients [see Use In Specific Populations].

Colonic Mucosal Ulceration, Ischemic Colitis And Ulcerative Colitis

Osmotic laxatives may produce colonic mucosal aphthous ulcerations, and there have been reports of more serious cases of ischemic colitis requiring hospitalization. Concurrent use of stimulant laxatives and PLENVU may increase the risk and is not recommended. Consider the potential for mucosal ulcerations resulting from the bowel preparation when interpreting colonoscopy findings in patients with known or suspected inflammatory bowel disease.

Use In Patients With Significant Gastrointestinal Disease

If gastrointestinal obstruction or perforation is suspected, perform appropriate diagnostic studies to rule out these conditions before administering PLENVU [see CONTRAINDICATIONS]. Use with caution in patients with severe ulcerative colitis.

Aspiration

Patients with impaired gag reflex or other swallowing abnormalities are at risk for regurgitation or aspiration of PLENVU. Observe these patients during the administration of PLENVU. Use with caution in these patients.

Do not combine PLENVU with starch-based thickeners [see DOSAGE AND ADMINISTRATION]. Polyethylene glycol (PEG), a component of PLENVU, when mixed with starch- thickened liquids reduces the viscosity of the starch-thickened liquid. When a PEG- based product used for another indication was mixed in starch-based pre-thickened liquids used in patients with dysphagia, thinning of the liquid occurred and cases of choking and potential aspiration were reported.

Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency

Since PLENVU contains sodium ascorbate and ascorbic acid, PLENVU should be used with caution in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, especially G6PD deficiency patients with an active infection, with a history of hemolysis, or taking concomitant medications known to precipitate hemolytic reactions.

Risks In Patients With Phenylketonuria

Phenylalanine can be harmful to patients with phenylketonuria (PKU). PLENVU contains phenylalanine, a component of aspartame. Each PLENVU treatment contains 491 mg of phenylalanine. Before prescribing PLENVU to a patient with PKU, consider the combined daily amount of phenylalanine from all sources, including PLENVU.

Hypersensitivity Reactions

PLENVU contains PEG and may cause serious hypersensitivity reactions including anaphylaxis, angioedema, rash, urticaria, and pruritus [see ADVERSE REACTIONS]. Inform patients of the signs and symptoms of anaphylaxis, and instruct them to seek immediate medical care should signs and symptoms occur.

Patient Counseling Information

Advise the patient to read the FDA-approved patient labeling (Medication Guide and Instructions for Use).

Instruct patients:

  • That two doses of PLENVU are required for a complete preparation for colonoscopy either as a Two-Day Split-Dosing or One-Day Morning Dosing Regimen [see INSTRUCTIONS FOR USE].
  • Not to take other laxatives while they are taking PLENVU.
  • That PLENVU contains 491 mg of phenylalanine per treatment [see WARNINGS AND PRECAUTIONS].
  • That each pouch needs to be reconstituted in water before ingestion and that they should drink additional clear liquids. Examples of clear liquids can be found in the Instructions for Use.
  • Not to take oral medications within one hour of starting each dose of PLENVU.
  • To follow the directions in the Instructions for Use, for either the Two-Day Split-Dosing or the One-Day Morning Dosing Regimen, as prescribed.
  • To consume additional clear liquids before, during, and after the use of PLENVU to prevent dehydration [see WARNINGS AND PRECAUTIONS].
  • To contact their healthcare provider if they develop significant vomiting or signs of dehydration after taking PLENVU or if they experience altered consciousness or seizures [see WARNINGS AND PRECAUTIONS].
  • Not eat or drink alcohol, milk, anything colored red or purple or any other foods containing pulp material.
  • To stop drinking PLENVU temporarily or drink each portion at longer intervals if they develop severe abdominal discomfort or distention until these symptoms diminish. If severe symptoms persist, tell patients to contact their healthcare provider.

Use In Specific Populations

Pregnancy

Risk Summary

There are no available data with PLENVU in pregnant women to inform a drug-associated risk for adverse developmental outcomes. Animal reproduction studies have not been conducted with PLENVU.

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Lactation

Risk Summary

There are no data available to assess the presence of PLENVU in human milk, the effects on the breastfed child or the effects on milk production. The lack of clinical data during lactation precludes a clear determination of the risk of PLENVU to a child during lactation; therefore, the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for PLENVU and any potential adverse effects on the breastfed child from PLENVU or from the underlying maternal condition.

Pediatric Use

The safety and effectiveness of PLENVU in pediatric patients has not been established.

Geriatric Use

Of the approximately 1000 patients in clinical trials receiving PLENVU, 217 (21%) patients were over 65 years of age. No overall differences in safety or effectiveness were observed between geriatric patients and younger patients, and other reported clinical experience has not identified differences in responses between geriatric patients and younger patients. However, elderly patients are more likely to have decreased hepatic, renal or cardiac function and may be more susceptible to adverse reactions resulting from fluid and electrolyte abnormalities [see WARNINGS AND PRECAUTIONS].

Renal Impairment

Use PLENVU with caution in patients with renal impairment or patients taking concomitant medications that may affect renal function [see DRUG INTERACTIONS]. These patients may be at risk for renal injury. Advise these patients of the importance of adequate hydration before, during and after the use of PLENVU, and consider performing baseline and post-colonoscopy laboratory tests (electrolytes, creatinine, and BUN) in these patients [see WARNINGS AND PRECAUTIONS].

Overdosage & Contraindications

OVERDOSE

Overdosage of more than the recommended dose of PLENVU may lead to severe electrolyte disturbances, as well as dehydration and hypovolemia, with signs and symptoms of these disturbances [see WARNINGS AND PRECAUTIONS]. Monitor for fluid and electrolyte disturbances and treat symptomatically.

CONTRAINDICATIONS

PLENVU is contraindicated in the following conditions:

  • Gastrointestinal (GI) obstruction [see WARNINGS AND PRECAUTIONS]
  • Bowel perforation [see WARNINGS AND PRECAUTIONS]
  • Gastric retention
  • Ileus
  • Toxic megacolon
  • Hypersensitivity to any ingredient in PLENVU [see WARNINGS AND PRECAUTIONS]
Clinical Pharmacology

CLINICAL PHARMACOLOGY

Mechanism Of Action

The primary mode of action is osmotic action of the components of PLENVU (PEG 3350 plus sodium sulfate components in Dose 1, and sodium ascorbate and ascorbic acid plus PEG 3350 components in Dose 2) which induce the laxative effect. The physiological consequence is increased water retention in the lumen of the colon, resulting in loose stools.

Pharmacodynamics

The osmotic effect of the unabsorbed PEG, ascorbate and sulfate ions, when ingested, produces a copious watery diarrhea.

The first bowel movement may happen about 1 to 2 hours after the start of PLENVU intake.

Pharmacokinetics

The plasma pharmacokinetic parameters for PEG 3350, ascorbate and sulfate are shown in Table 4.

Table 4: Plasma Pharmacokinetic Data Following Two-Day Split-Dosing Regimen of 140 grams PEG 3350, 33.9 grams Sodium Ascorbate, 9 grams Sodium Sulfate, 20.1 grams Ascorbic Acid, 4.8 grams Sodium Chloride and 2.3 grams Potassium Chloride in Healthy Subjects1 (N=21)2

PK Parameter PEG 3350
Mean (SD)
Ascorbate3
Mean (SD)
Sulfate3
Mean (SD)
Cmax [mcg/mL] 2.7 (1.17) 70.8 (22.37) 17.6 (4.80)
tmax [h] 3.0 (0.61) 16.8 (0.75) 8.1 (5.51)
AUC(0-tlast) [(mcg/mL)*h] 17.3 (7.19) 433.1 (157.29) 206.2 (74.32)
Vd [l] 48,481 (29,811) 1,026 (675) 231 (205)
t1/2 [h] 4.1 (2.34) 7.2 (6.16) 10.5 (15.19)
1 Four-day study with controlled diet including fasting from 2 pm on Day 1 to 2 pm on Day 2.
2 Product studied contains the same amount of PEG 3350 and sodium sulfate, although the amount of sodium ascorbate and ascorbic acid are slightly different, compared to PLENVU.
SD = standard deviation; Cmax = maximum concentration; tmax = time to maximum concentration from start of dosing; AUC(0-tlast) = area under the curve from t0 to tlast; Vd = volume of distribution; t1/2 = half-life.
3 Baseline-corrected

A pharmacokinetic study measured up to 85% to 99% of a 140 grams oral PEG 3350 dose in excreted feces.

A pharmacokinetic study measured up to 69% of a 50 grams oral ascorbate dose in excreted feces and up to 5% of the 50 grams oral ascorbate dose is recovered in the urine (with up to 0.07% as the ascorbate metabolite, oxalic acid).

Sulfate is endogenous and also present in the diet. A pharmacokinetic study measured up to 69% to 73% of a 9 grams oral sodium sulfate dose in excreted feces, with approximately 43% recovered in the urine.

Clinical Studies

Study Design

The colon cleansing efficacy, safety and tolerability of PLENVU was evaluated in two randomized, parallel-group, multicenter, investigator-blinded trials in adult patients scheduled to undergo a screening, surveillance, or diagnostic colonoscopy. The overall patient population consisted of 49% male and 51% female patients, mean age of 56 years (range 18 to 86 years), 92% Caucasian, 5% Black and 2% Asian. In general, the demographic characteristics were balanced across the trials.

In Study NER1006-01/2014 (referred to as NOCT; NCT02254486) and Study NER1006-02/2014 (referred to as MORA; NCT02273167), the bowel cleansing efficacy of PLENVU was compared to two different comparators (Table 5) using two different PLENVU dosing regimen(s):

  • PLENVU Two-Day Split-Dosing Regimen allows for an overnight gap between doses (Dose 1 taken in the evening before the colonoscopy, between approximately 4 pm and 8 pm, and Dose 2 the next morning, on the day of the colonoscopy, approximately 12 hours after the start of Dose 1).
  • PLENVU One-Day Morning Dosing Regimen gives both doses the morning of the day of colonoscopy (Dose 1 between approximately 3 am and 7 am, and Dose 2 a minimum of 2 hours after the start of Dose 1).

Table 5: Treatment Regimens by Trial

Trial PLENVU Regimen(s) Comparator Regimens
NOCT Two-Day Split-Dosing Trisulfate bowel cleansing solution administered as a Two-Day Split-Dosing Regimen:
  • [Trisulfate (Two 6 ounce bottles each containing sodium sulfate 17.5 grams, potassium sulfate 3.13 grams, and magnesium sulfate 1.6 grams)]
MORA Two-Day Split-Dosing

and

One-Day Morning Dosing
2 liter PEG + electrolytes (2 L PEG+E) preparation administered as a Two-Day Split-Dosing Regimen:
  • Two doses, each containing PEG 3350 100 grams, sodium sulfate 7.5 grams, sodium chloride 2.691 grams, potassium chloride 1.015 grams, sodium ascorbate 5.9 grams, and ascorbic acid 4.7 grams

Primary Endpoint

The primary efficacy endpoint in both trials was the proportion of patients achieving “overall bowel cleansing success,” which was defined by a result of Grade A or B (Grades A or B [see Table 6] corresponding to full visualization of the bowel mucosa on the Harefield Cleansing Scale [HCS]), as assessed on withdrawal of colonoscope. The HCS segmental scores were initially evaluated by the colonoscopist at the site, who was blinded to treatment, and evaluated for endpoint analysis by central readers (gastroenterologists) using video recordings of the colonoscopy.

Table 6: Harefield Cleansing Scale

Overall Grade Description
A All five segments* scored 3 or 4
(Mucosa is fully visualized without cleaning.)
B One or more segments scored 2, remaining segments scored 3 or 4
(Mucosa is fully visualized.)
C One or more segments scored 1, remaining segments scored 2, 3 or 4
D One or more segments scored 0
Segmental Score Description
4 Empty and clean
3 Clear liquid
2 Brown liquid/fully removable semisolid stools
1 Semisolid, only partially removable stools
0 Irremovable, heavy, hard stools
* Colon ascendens, Colon transversum, Colon descendens, Colon sigmoideum, Rectum

Statistical Analysis

The modified Intent-to-Treat (mITT) population was used as the primary population for the efficacy analyses and was defined as all randomized patients with the exception of any patient who (i) was randomized but subsequently failed to meet entry criteria and (ii) in whom it was confirmed (from their patient diary) that the same patient did not receive any study drug.

Non-inferiority was assessed using a one-sided 97.5% confidence interval (CI) for the difference in proportions of patients for the overall bowel cleansing success endpoint. Non-inferiority was demonstrated if the difference between PLENVU and the comparator was above the predefined non-inferiority margin set at -10%.

Efficacy Results

The results for the overall bowel cleansing success endpoint in the mITT population in NOCT are shown in Table 7. The Two-Day Split-Dosing regimen of PLENVU was shown to be non-inferior (NI) to the trisulfate solution comparator.

Table 7: Overall Bowel Cleansing Success Rate of PLENVU versus Trisulfate in NOCT

Primary Endpoint
(N=556)
PLENVU
Two-Day Split-Dosing
Trisulfate
Two-Day Split-Dosing
PLENVU® - Trisulfate
Difference (%)
(N=276)
n (% = n/N*100)
(N=280)
n (% = n/N*100)
(97.5% One-Sided Lower Confidence Interval)
Overall Colon 235 238 0.1%
Cleansing Success Rate (85.1%) (85.0%) (-8.2%)

The results for the overall bowel cleansing success endpoint in the mITT population in MORA are shown in Table 8. Both the PLENVU Two-Day Split-Dosing regimen and the PLENVU One-Day Morning Dosing regimen were shown to be non-inferior (NI) to the 2 L PEG+E treatment comparator.

Table 8: Overall Bowel Cleansing Success Rate of PLENVU versus 2 L PEG+E in MORA

Primary Endpoint
(N=822)
PLENVU
Two-Day Split-Dosing
PLENVU
One-Day Morning Dosing
2 L PEG+E
Two-Day Split-Dosing
PLENVU®
Regimen - 2 L PEG+E
Difference (%)
(N=275)
n (% = n/N*100)
(N=275)
n (% = n/N*100)
(N=272)
n (% = n/N*100)
(97.5% One-Sided Lower Confidence Interval)
Overall Colon Cleansing Success Rate 253 (92.0%) 245 (89.1%) 238 (87.5%) Two-Day Split-Dosing
4.5%
(-4.0%)
One-Day Morning Dosing
1.6%
(-6.9%)

Medication Guide

PATIENT INFORMATION

No information provided. Please refer to the WARNINGS AND PRECAUTIONS section.

FDA Logo

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Health Solutions From Our Sponsors